公开(公告)号：US20240316024A1

公开(公告)日：2024-09-26

申请号：US18443907

申请日：2024-02-16

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Lori Jean Patterson ,  Eric L. Strangeland ,  Sheila Zipfel ,  Daniel D. Long

IPC: A61K31/4465 ,  C07D211/22 ,  C07D211/32

CPC classification number: A61K31/4465 ,  C07D211/22 ,  C07D211/32

Abstract: The invention relates to compounds of formula I:




where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

公开(公告)号：US09260414B2

公开(公告)日：2016-02-16

申请号：US14539039

申请日：2014-11-12

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Robert Murray McKinnell ,  Daniel D. Long ,  Lori Jean Van Orden ,  Lan Jiang ,  Mandy Loo ,  Daisuke Roland Saito ,  Sheila Zipfel ,  Eric L. Stangeland ,  Kassandra Lepack ,  Gavin Ogawa

IPC: A61K31/496 ,  C07D401/14 ,  C07D403/14 ,  A61K45/06

CPC classification number: C07D401/14 ,  A61K31/496 ,  A61K45/06 ,  C07D403/14

Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.

Abstract translation: 本发明提供式（I）化合物：其中变量在说明书中定义，或其药学上可接受的盐，其是丙型肝炎病毒的复制抑制剂。 本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗丙型肝炎病毒感染的方法，以及可用于制备这些化合物的方法和中间体。

公开(公告)号：US20180050024A1

公开(公告)日：2018-02-22

申请号：US15591419

申请日：2017-05-10

Applicant: THERAVANCE BIOPHARMA R&D IP, LLC

Inventor： Lori Jean Patterson ,  Eric L. Stangeland ,  Sheila Zipfel ,  Daniel D. Long

IPC: A61K31/4465 ,  C07D211/22 ,  C07D211/32

CPC classification number: A61K31/4465 ,  C07D211/22 ,  C07D211/32

Abstract: The invention relates to compounds of formula I: where a, R1, and R3-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.